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Abstract
Introduction
There is considerable variation in selection of patients for and type of neoadjuvant 
radiotherapy administered in the treatment of resectable rectal cancer. The aim of this 
study was to report outcomes for patients with resected rectal cancer from a unit with step-
wise selection for surgery alone, short course radiotherapy (SCRT) or downstaging 
chemoradiotherapy (LCCRT).
Material and Methods
Cohort analysis of patients with rectal adenocarcinoma resected with curative intent 
between 2008 and 2012 at a specialist regional colorectal surgery centre. The primary 
endpoints were local recurrence, metastatic recurrence, disease-free survival and overall 
survival. Exploratory uni- and multi-variable regression analyses were performed to identify 
predictive factors.
Results
Two-hundred and forty patients were treated by surgery alone, 90 patients received SCRT 
and 91 patients received LCCRT. Five-year local recurrence was 10.8% in the surgery alone 
group, 3.3% in the SCRT and 18.7% with LCCRT. Metachronous distant metastasis was 
highest in the SCRT group (13.8% surgery alone, 25.6% SCRT, 15.4% LCCRT). Uni- and multi-
variable regression analysis found that local and distant recurrence was attributable 
predominantly to adverse tumour biology.
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Conclusion
Patients selected for SCRT had a lower rate of local recurrence than patients selected for 
surgery alone, but were more likely to develop distant metastasis. There was no difference 
in overall survival. With low local recurrence rates, distant metastasis is the predominant 
risk for patients with resectable rectal cancer.
Keywords: neoadjuvant radiotherapy, surgery, rectal adenocarcinoma, rectal cancer
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Introduction
There is considerable world-wide variation in selection of patients for neoadjuvant 
radiotherapy in rectal cancer. ‘Downstaging’ long course chemoradiotherapy (LCCRT) is the 
most commonly used modality worldwide. In some centres it is given to all patients with 
stage II or III disease, in others reserved for locally advanced tumours with predicted surgical 
margin involvement to achieve operability with a negative circumferential resection margin 
(CRM). Short course radiotherapy (SCRT; 25Gy in five fractions over 1 week followed by 
immediate surgery) originated in Northern Europe, is easier to deliver and achieves similar 
local control to LCCRT [1-5]. However, surgery alone can achieve low rates of local 
recurrence in carefully selected patients with stage I-III disease [6, 7]. Even within the 
English National Health Service (NHS), the proportion of patients with surgically treated 
rectal cancer receiving some form of radiotherapy ranged from 5% to 78%, confirming 
considerable variation in practice between different hospital cancer multidisciplinary 
meetings (MDM) [8].
Neoadjuvant radiotherapy for rectal cancer is given to reduce local recurrence. Apart from 
the first Swedish trial, in which local recurrence in the control arm was exceptionally high, it 
has not been shown to improve cancer-related or overall survival. Furthermore, a non-
selective approach to neoadjuvant radiotherapy carries a significant risk of over-treating 
patients with low risk tumours, exposing them to short and long term adverse effects on 
bowel and genitourinary function [9, 10]. 
Given the lack of consensus on management of rectal cancer it is important that clinical trial 
results are backed up by data from daily practice. Here we report 5-year outcomes for rectal 
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cancer surgery from a regional UK colorectal cancer centre in which patients are selected for 
surgery alone, SCRT or LCCRT based on clinico-radiological assessment and MDM discussion.
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Material and Methods
Consecutive patients diagnosed with rectal adenocarcinoma and treated via the Lothian 
Colorectal Cancer MDM at the Western General Hospital, Edinburgh, between 1st January 
2008 and 31st December 2012, were identified from the prospectively-compiled Southeast 
Scotland Cancer Network (SCAN) registry. This MDM is the sole centre for treatment of 
rectal cancers in Lothian region (population 850,000). Hospital electronic patient records 
were interrogated to retrieve additional data not provided by the database, including 
patient demographics, pre-operative staging, neoadjuvant and adjuvant treatment, 
operation type and histopathology. Tumour location within the rectum was determined by 
clinical measurement from the anal verge where this was recorded and dichotomised to 
upper rectum (≥10cm) or mid/lower rectum (<10cm); if absent, a determination of tumour 
location was made from clinical information (e.g. palpable tumours were deemed to lie in 
the mid/lower rectum) or MRI scan reports. Socioeconomic status quintiles were obtained 
from the Scottish Index of Multiple Deprivation Postcode Lookup function 
(http://www.gov.scot/Topics/Statistics/SIMD/SIMDPostcodeLookup). Primary outcomes 
were local recurrence, distant metastatic recurrence, disease- free survival and overall 
survival. Date of death was obtained from hospital electronic patient records, which are 
updated from National Records Scotland daily. Date of local or distant recurrence was 
determined from date of first radiological or clinical diagnosis. 
Selection of patients for neoadjuvant radiotherapy was determined at a weekly MDM from 
clinical and radiological staging according to risk of local recurrence and proximity of tumour 
to the predicted CRM as per National Institute for Health and Clinical Excellence (NICE) 
guidelines.  Patients deemed at high risk for local recurrence (tumour at or within 1mm of 
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predicted resection margin, involved resection margin, T4 disease, N2 disease, extra-
mesenteric nodal disease, clinical fixity) received pre-operative LCCRT in the form of 45Gy in 
25 fractions over 6 weeks with sensitising capecitebine, followed by re-staging and a delay 
of 8-12 weeks to surgical resection.  Patients with contra-indications to chemotherapy 
agents but deemed high risk for local recurrence were treated with 20 fractions of 
radiotherapy over a four-week period (52.5 Gy) followed by delayed surgery.  For the 
purposes of this analysis these patients were included in the LCCRT group.  Patients with 
moderate risk of local recurrence (indicated by T3c/d tumour, and/orsuspicious mesorectal 
lymph nodes, and/orintramesenteric extramural vascular invasion) with non-threatened 
resection margins received SCRT (5x5Gy over 5 consecutive days) with resection 7-10 days 
after completion of treatment.  Those deemed low risk (cT1-T3a disease, cN0) received 
surgery alone.  Upper rectal tumours were treated as sigmoid colon cancers in most cases 
and were considered for neoadjuvant radiotherapy in only selected cases. All patients 
included in the main analysis had disease confined to the pelvis at the time of resection.
Selected patients with stage I rectal cancers were offered organ-preserving local resection 
by standard open transanal surgery or transanal endoscopic micro-surgery (TEMS) as their 
first line management. Patients were considered for local resection if the lesion was staged 
as T1, less than 3cm diameter, located in the mid- or distal rectum, with favourable 
histology (moderate to well differentiation, no evidence of lymphovascular invasion).  Local 
resections were pre-dominantly reserved for patients with significant co-morbidities 
deemed unfit for major resection.  Patients with polyp cancers (endoscopically completely 
excised adenomas containing a malignant focus) were managed depending on presence of 
conventional high risk features. Patients who underwent organ-preserving local resection 
are not included in these results. Patients who underwent local resection by any technique 
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followed immediately by radical resection are included in the cohort described in this 
report.
Adjuvant chemotherapy was offered to patients with pathological stage III disease and high-
risk stage II disease (extramural vascular invasion, poorly differentiated or T4 primary 
tumour). Patients who had received downstaging LCCRT with significant or complete 
response were considered for adjuvant treatment based on clinicoradiological staging prior 
to radiotherapy. 
Follow-up for patients managed with curative intent comprised 6-monthly clinic review for 4 
years, two IV contrast-enhanced CT scans of the chest, abdomen and pelvis within the first 3 
years, colonoscopic surveillance and 6-monthly serum carcinoembryonic antigen 
measurement.  Patients with resectable metachronous metastatic disease were referred to 
the organ-specific MDM for further management, otherwise recurrent disease was 
managed with palliative intent.
A positive CRM was defined by histopathology as cancer <1mm from the ink-stained surgical 
resection margin (primary tumour or lymph node). Local recurrence was defined as tumour 
regrowth within the pelvis or perineum. Local recurrence analyses were performed on all 
eligible patients who underwent a macroscopically complete local resection.
Time-to-event analyses were calculated from date of diagnosis. Patients were censored at 
their last documented follow-up or hospital contact. Disease-free survival was calculated as 
time to first recurrence, local or distant. Overall survival was calculated as time from 
diagnosis to death by any cause using SPSS 24.0, comparing groups using Kaplan-Meier 
method and the log-rank test. Competing risk analysis was performed using methods 
proposed by Fine and Gray [11]. With death as a competing event, the cumulative incidence 
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rate was estimated for local recurrence, distant metastatic recurrence and disease-free 
survival. Gray's test was used to determine the significance of difference across patients 
treated by surgery alone, SCRT or LCCRT [11]. Univariable competing risk regression was 
used to estimate hazard ratios of variables known to be associated with recurrence/survival 
using data from the surgery alone and SCRT sub-groups only (n=330), excluding the LCCRT 
group because pathological variables are not representative of the pre-treatment primary 
cancer (the intention of radiotherapy being to downstage the tumour). Exploratory multi-
variable regression was conducted using a backward stepwise model selection approach 
using two blocks to fit a competing risk model [12]. In this analysis, the BICcr criteria are 
modified based on Bayesian information criteria (BIC) to fit competing risk data where a log-
transformed number of events instead of the sample size is used as the penalty parameter 
[13].  For overall survival, multi-variable analysis Cox proportional hazard regression 
backward stepwise (conditional LR) models were adopted. The first block comprised 
demographic (age, sex, SIMD quintile), surgical (operation: abdominoperineal excision of 
rectum (APER) v other; tumour location; plane of excision; positive CRM) and pathological 
data. The second block contained treatment variables (radiotherapy, chemotherapy). In 
order to overcome the issue of collinearity between multiple pathology variables, an 
‘Adverse Tumour’ variable was created as a single composite categorical indicator of a poor 
prognosis tumour, defined by presence of any of the following adverse features: poor 
differentiation; T4; EMVI positive; N2/N2+. Analysis using an additive ordinal scale of these 
was explored but discarded due to a low number of cases scoring 3 or 4 points.
All competing risk analyses were performed in R (version 3.3.0) using the package 'cmprsk' 
[14].  With death as a competing event, the 5-year cumulative incidence rate was estimated 
and plotted for local recurrence and distant metastatic recurrence. 
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Results
Between 1st Jan 2008 and 31st December 2012 a total of 691 patients diagnosed with 
primary rectal adenocarcinoma were managed via the Lothian Colorectal Cancer MDM at 
the Western General Hospital, Edinburgh. Seventy-five (11%) patients underwent local 
excision via endoscopy, transanal polypectomy, or transanal endoscopic microsurgery 
(TEMS), and did not require, or were not fit for, subsequent radical resection. In all, 149 
(22%) patients were treated with palliative intent from diagnosis, either as a consequence of 
metastatic disease at presentation, comorbidity which precluded surgical resection, or both. 
These patients were considered for defunctioning stomas, palliative radiotherapy, or 
supportive measures only depending on presentation. 
Four hundred and sixty-seven patients underwent resection of the primary rectal cancer, of 
which 46 patients underwent resection in the presence of distant visceral or peritoneal 
metastasis, or clearly palliative resection of locally advanced/perforated disease. The 
remaining cohort of 421 patients (276 male (65.6%): 145 female) underwent surgical 
resection of the primary rectal cancer with curative intent. The mean age of the cohort was 
66 years (SD 11.6, range 24-93 years). 
Patient demographic, treatment and pathology variables by mode of neoadjuvant 
radiotherapy are shown in Table 1. Two hundred and forty (57%) patients were selected for 
surgery alone. Neoadjuvant short course radiotherapy (SCRT) was administered to 90 
patients (22%) and neoadjuvant radiotherapy with down-staging intent (LCCRT) to 91 
patients (21%). The overall permanent stoma rate (defined as a stoma which had not been 
reversed within 1 year of cancer resection) for the whole cohort was 35.2% (148/421). This 
number included a permanent stoma rate after initial restorative surgery of 15.5% (50/323). 
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Over half of the cohort was from the 4th and 5th SIMD quintiles (5=least deprived), indicating 
less deprivation, and hence better health status, than in some other regions of Scotland. 
There was no difference in SIMD quintile distribution in patients selected for surgical 
resection compared with the total cohort (p=0.712) and no relationship between SIMD 
quintile and oncological outcomes (Table 2 and Supplementary material). 
Neoadjuvant radiotherapy was used much less frequently for upper rectal tumours 
compared to tumours in the middle and lower thirds of the rectum. A pathological positive 
resection margin (R1 resection) was identified in 38/421 (9.0%) patients. In 31 patients the 
positive resection margin was the primary tumour and in 7 patients a mesenteric lymph 
node. The rate of a positive resection margin was 4.4% (4/91) for upper rectal cancers and 
10.3% (34/330) for cancers located in the mid/lower rectum (p=0.082).
There was complete pathological response to LCCRT in 13 of 91 (14.3%) patients. One 
patient had complete pathological response of the primary tumour but two positive lymph 
nodes were identified in the mesorectum. 
In total 46 patients (10.9%) developed local recurrence. Of these, 16 patients had already 
developed metastatic disease prior to detection of local recurrence. Nine patients 
developed local recurrence (median interval from primary surgery to diagnosis of local 
recurrence 30 months, range 11-61 months) followed by distal metastatic disease after a 
further median interval of 14 months (range 4-53 months). True isolated recurrence without 
metastatic disease occurred in 21 patients (5%) after a median interval from primary surgery 
of 28 months (range 8-74 months).
The mean age (SD) of patients receiving adjuvant chemotherapy was 61.5 (10.6) years 
compared to 68.2 (11.5) years in those that did not. 
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Time-to-event survival analyses
Local recurrence was least frequent in the SCRT group compared to surgery alone or LCCRT 
(Figure 1). However, the SCRT group had the highest rate of distant metastasis (Figure 2). 
There was no difference in disease-free or overall survival between the groups.
Exploratory uni- and multi-variate competing risk regression analysis
In univariate analysis, pathology variables were much more strongly associated with 
oncological outcomes than treatment variables (Supplementary material).
In multivariate modelling, adverse tumour biology was the strongest predictive variable for 
local recurrence, distant metastasis, disease-free survival and overall survival. A positive 
CRM was an independent predictor of distant metastasis, disease-free survival and overall 
survival but not local recurrence. SCRT was predictive of reduced local recurrence. Male 
patients were more likely to develop distant metastases (Table 2).
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Table 1: Demographic, treatment and histopathology data by mode of neoadjuvant 
treatment
Surgery 
alone 
(n=240)
SCRT (n=90) LCCRT (n=91)
Age (years) 
(median (range))
69 (33-93) 66.5 (40-82) 65 (24-83)
Male:female 
ratio
158: 82 58: 32 60: 31
Operation Anterior resection
202 (84.2%) 68 (75.6%) 50 (54.9%)
Abdomino-
perineal excision
20 (8.3%) 19 (21.1%) 33 (36.3%)
Hartmann’s 10 (4.2%) 2 (2.2%) 5 (5.5%)
Other* 8 (3.3%) 1 (1.1%) 3 (2.2%)
Tumour height Upper third 
rectum
82 (34.2%) 3 (3.3%) 6 (6.6%)
Mid/lower thirds 
of rectum
158 (65.8%) 87 (96.7%) 85 (93.4%)
Positive 
resection 
margin
13(5.4%) 9 (10.0%) 16 (17.6%)
Plane of surgery Intramesorectal/ 
muscularis 
propria
36 (16.7%) 21 (23.3%) 20 (22.0%)
Complete 
mesorectal fascia
180 (83.3%) 69 (76.7%) 71 (78.0%)
Not reported 24 0 0
pT stage y0 0 0 14 (15.4%)
1 23 (9.6%) 3 (3.3%) 1 (1.1%)
2 70 (29.2%) 19 (21.1%) 20 (22.0%)
3 122 (50.8%) 62 (68.9%) 47 (51.6%)
4 25 (10.4%) 6 (6.7%) 9 (9.9%)
pN stage N0 149 (62.1%) 51 (56.7%) 58 (63.7%)
N1 59 (24.6%) 26 (28.9%) 23 (25.3%)
N2 32 (13.3%) 13 (14.4%) 10 (11.0%)
TNM stage I 78 (32.5%) 17 (18.9%) 16 (17.6%)
Page 13 of 27
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
II 71 (29.6%) 34 (37.8%) 29 (31.9%)
III 91 (37.9%) 39 (43.3%) 33 (36.3%)
Complete 
pathological 
response
- - 13 (14.3%)
EMVI positive 63 (26.3%) 31 (34.4%) 14 (15.4%)
Tumour grade Poorly 
differentiated
16 (6.9%) 13 (14.6%) 9 (11.0%)
Well/moderately 
differentiated
215 (93.1%) 76 (85.4%) 67 (88.2%)
Missing/ not 
reported
9 1 15
Local recurrence 26 (10.8%) 3 (3.3%) 17 (18.7%)
Distant 
recurrence
33 (13.8%) 23 (25.6%) 14 (15.4%)
Adjuvant 
chemotherapy
65 (27.1%) 30 (33.3%) 52 (57.1%)
*1xProctectomy, 5xPanproctocolectomy and ileostomy, 2xPanproctocolectomy and IPAA, 3xPelvic 
exenteration, 1xTotal colectomy and ileorectal anastomosis.
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Table 2: Exploratory multivariate regression analysis of rectal cancer variables in patients 
(n=330) receiving surgery alone or short-course radiotherapy (SCRT)
HR, 95% CI P
Local Recurrence SCRT 0.274(0.082-0.914) 0.035
‘Adverse tumour’ 2.924(1.387-6.165) 0.005
Distant Metastasis Male sex 1.880(1.010-3.498) 0.046
SCRT 1.918(1.127-3.265) 0.016
CRM positive 2.491(1.239-5.018) 0.011
‘Adverse tumour’ 2.992(1.644-5.446) 0.0003
Disease-free survival CRM positive 3.044(1.571-5.898) 0.001
‘Adverse tumour’ 2.768(1.651-4.642) 0.0001
Overall survival Age 1.034 (1.014-1.053) 0.001
CRM positive 2.696 (1.483-4.901) 0.001
‘Adverse tumour’ 2.123 (1.382-3.256) 0.001
Page 15 of 27
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Discussion
This analysis reports the results of a consecutive cohort of rectal cancer patients treated 
over a 5-year period by surgical resection with curative intent, using a selective policy for 
short course or downstaging neoadjuvant radiotherapy. By definition, the groups that 
received surgery alone, SCRT, and LCCRT were not directly comparable because they were 
actively selected at the outset based on preoperative clinical/radiological staging. This 
analysis explores the relative contributions of radiotherapy, surgery, and tumour biology 
(pathology) to the overall outcomes. 
Short course radiotherapy achieved significantly reduced local recurrence compared to 
patients selected for surgery alone. However, the SCRT group was more likely to develop 
distant metastatic disease than either the surgery alone group or the LCCRT group. Given 
that the SCRT group was selected on the basis that the primary tumour appeared more 
locally advanced on clinic-pathological staging than in the surgery alone group, it would be 
expected that systemic disease would be more likely than in the surgery alone group. 
However, that distant metastasis was greater than in the LCCRT group (the most locally 
advanced tumours) was unexpected. Selection for SCRT may have inadvertently identified a 
subgroup with greater propensity to systemic rather than local relapse, whereas those 
selected for LCCRT were perhaps more likely to advance locally than metastasise. It is also 
possible that the longer period of treatment required for LCCRT, and subsequent restaging, 
enriched this subgroup for more favourable tumour biology. However, only 7 patients 
received LCCRT with the intention of proceeding to surgery but were not resected due to 
local progression/non-response (3 patients) or development of systemic metastases (4 
patients) during treatment (these patients are included in the 149 patients treated with 
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palliative intent). Twice as many LCCRT patients received adjuvant chemotherapy compared 
to SCRT patients, although the SCRT group contained some patients unfit for chemotherapy 
due to comorbidity.
Quality of surgery is a key determinant of outcome in rectal cancer surgery; indeed, new 
operations have arisen to overcome shortcomings in standard surgical technique (e.g. extra-
levator perineal excision of rectum (ELAPE)) [15].  The surgical variables available in this 
dataset suggest that surgery was of reasonable quality: 80% of resections had a complete 
mesorectum and the overall positive resection margin was 9.0%. By comparison, the 
positive CRM rate was 15.2% in the UK MRC CLASICC study [16], 16% in the Dutch TME trial 
[17], 12% in a Danish short course radiotherapy registry report [18] and 10% in the CR07 
trial [3].  A complete mesorectal excision, without defects, was achieved in 73.5% % in the 
COREAN study [19] and 52% in the CR07 trial [20].  Surgical factors which have been cited in 
previous reports as being associated with adverse outcomes, such as the type of operation 
(APER vs. anterior resection) [21], tumour location within the rectum (upper vs lower), or 
quality of mesorectal excision [20], were not risk factors for adverse survival outcomes in 
this cohort.
The main predictors of oncological outcome were pathological: poor differentiation, higher 
T and N stage and EMVI were all strongly associated with recurrence. As in the CR07 trial, a 
positive CRM was not independently predictive of local recurrence [20]. However, it was 
predictive of systemic disease recurrence, suggesting co-linearity of more locally advanced 
tumours with poor biological phenotype and therefore more difficult resection, rather than 
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poor quality surgery. In predicted medium-risk tumours, SCRT was effective in reducing local 
recurrence and hence negating a positive CRM as an independent risk factor.
The SCRT group had more advanced TNM staging and adverse histological features than 
patients selected for surgery alone. Nevertheless, over 50% of patients receiving SCRT were 
pathological stage I or II cancers, and hence over-staged by current assessment techniques. 
Although the surgery alone group contained a number of advanced tumours suggesting 
under-staging, many of these were upper rectal cancers which would not have been 
considered for neoadjuvant radiotherapy. As noted in other recent reports, preoperative 
nodal staging remains inaccurate [22]. This has implications if the Dutch TME subgroup 
analysis showing 10% survival advantage in node positive CRM negative patients that 
received radiotherapy is borne out in further analysis. Patients in the CR07 study that were 
CRM negative but node positive had local recurrence of 20% in 10 years. Better techniques 
for preoperative nodal staging are required.
A strength of this analysis is that it combines data granularity with a reasonably large 
cohort, and as the sole regional centre for management of rectal cancer there should be 
minimal loss of data for a retrospective study. We have reported the management of the 
entire rectal cancer cohort over this time period to set the cases selected for surgery in 
context. There was no association between socioeconomic status (SIMD) and selection for 
curative resection or oncological outcomes, suggesting that access to treatment across the 
region was equitable. However, it is difficult to overcome data collinearity: adverse 
pathological features tended to be aggregated in poor prognosis tumours and adjuvant 
treatments were selected based on clinical or pathological variables. Some variables (e.g. 
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Glasgow Prognostic Score, surgical complications) that have been shown to impact outcome 
were not available. Therefore, multivariate regression analyses should be interpreted with 
caution. Furthermore, no data on short- or long-term toxicity or treatment adjustments 
were available (other than reporting the number of cases that did not progress to surgery 
following LCCRT, see above). Our selection policy avoided neoadjuvant radiotherapy 
in >50% of the cohort; in the remainder we assume toxicities would be similar to existing 
data [9, 23].
In conclusion, neoadjuvant SCRT reduces local recurrence in resectable rectal cancer but 
selection remains suboptimal. Tumour biology has greater influence on outcomes than 
treatment variables. Distant metastasis is far more likely than local recurrence for patients 
with resectable disease, and a strategy of SCRT followed by immediate surgery allows 
prompt progression to systemic treatment when indicated.
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Figure 1: Cumulative probability of local recurrence with deaths as competing events  
Number entering interval
Months: 0 12 24 36 48 60
Surgery 
alone
240 222 203 179 124 37
SCRT 90 86 79 69 44 16
LCCRT 91 90 80 72 56 27
Gray’s test: Surgery alone v SCRT Chi2 4.553, p=0.033; Surgery alone v LCCRT Chi2 
2.103, p=0.147; SCRT v LCCRT Chi2 8.839, p=0.003. 
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Figure 2: Cumulative probability of distant recurrence with deaths as competing events
Number entering interval
Months: 0 12 24 36 48 60
Surgery 
alone
240 224 202 180 124 38
SCRT 90 85 69 62 39 13
LCCRT 91 89 77 70 54 27
Gray’s test: Surgery alone v SCRT: Chi2 7.223, p=0.007; Surgery alone v LCCRT: Chi2 
0.014, p=0.905; SCRT v LCCRT Chi2 3.770, p= 0.052 
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Supplementary material: Univariate regression analysis of rectal cancer variables in patients 
(n=330) receiving surgery alone or short course radiotherapy (SCRT)
2.1 Local recurrence
HR (95% CI) p
Demographic Age 0.992(0.960-1.020) 0.620
Gender (male) 1.415(0.627-3.194) 0.400
SIMD quintiles vs. most 
deprived
0.578
2 2.105(0.243-18.245) 0.5
3 2.175(0.240-19.713) 0.49
4 3.864(0.493-30.310) 0.2
5 2.243(0.277-18.136) 0.45
Treatment SCRT vs. Surgery alone 0.297(0.090-0.987) 0.047
Adjuvant chemotherapy 1.260(0.588-2.697) 0.55
APER vs. other operation 0.523(0.126-2.164) 0.37
Upper third vs. mid/lower 0.486(0.233-1.014) 0.055
Incomplete mesorectal fascia 1.383(0.552-3.468) 0.49
Pathological Positive CRM 2.385(0.808-7.044) 0.12
Poor differentiation 
Nodal status (vs. N0) 0.937(0.364-2.412) 0.89
N1 2.436(1.038-5.713) 0.041
N2 1.445(0.699-2.987) 0.32
N+ vs. N- 4.275(1.893-9.651) 0.00047
Lymphovascular invasion 3.173(1.534-6.564) 0.0018
T3/4 vs. T0-2 7.372(1.737-31.280) 0.0067
Page 24 of 27
URL:http://mc.manuscriptcentral.com/SONC
Acta Oncologica
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
2.2 Distant metastasis 
HR (95% CI) p
Demographic Age 0.978(0.957-1.000) 0.05
Gender (male) 1.670(0.906-3.076) 0.1
SIMD quintile vs. most 
deprived
2 1.328(0.430-4.102) 0.62
3 1.658(0.542-5.073) 0.38
4 1.246(0.421-3.681) 0.69
5 0.889(0.293-2.704) 0.84
Treatment SCRT vs. Surgery alone 2.064(1.213-3.511) 0.0076
Adjuvant chemotherapy 1.868(1.106-3.153) 0.019
APER vs. other operation 1.998(1.037-3.847) 0.039
Upper third vs. mid/lower 0.917(0.522-1.608) 0.76
Incomplete mesorectal fascia 0.750(0.353-1.594) 0.45
Pathology Positive CRM 4.239(2.143-8.383) <0.0001
Nodal status (vs. N0)
N1 2.479(1.342-4.577) 0.0037
N2 4.201(2.174-8.117) <0.0001
N+ vs. N- 3.030(1.763-5.208) <0.0001
Poor differentiation 3.184(1.675-6.052) 0.00041
Lymph node ratio 11.226(4.908-25.679) <0.0001
Lymphovascular invasion 3.162(1.879-5.319) <0.0001
T3/4 vs. T0-2 3.440(1.644-7.196) 0.001
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2.3 Disease-free survival 
HR (95% CI) p
Demographic Age 0.982(0.962-1.003) 0.092
Gender (male) 1.246(0.868-1.791) 0.23
SIMD quintile vs. most 
deprived
2 1.526(0.510-4.567) 0.45
3 2.066(0.693-6.154) 0.19
4 1.709(0.601-4.859) 0.31
5 1.120(0.381-3.291) 0.84
Treatment SCRT vs. Surgery alone 1.414(1.069-1.870) 0.015
Adjuvant chemotherapy 1.729(1.068-2.799) 0.026
APER vs. other operation 1.670(0.905-3.080) 0.1
Upper third vs. mid/lower 0.827(0.494-1.387) 0.47
Incomplete mesor ctal fascia 0.905(0.472-1.736) 0.76
Pathology Positive CRM 4.635(2.499-8.597) <0.0001
Nodal status vs. N0
N1 1.781(1.007-3.153) 0.047
N2 3.978(2.247-7.045) <0.0001
N+ vs N- 2.459(1.523-3.971) 0.00023
Poor differentiation 4.056(2.333-7.051) <0.0001
Lymph node ratio 15.088(6.362-35.785) <0.0001
Lymphovascular invasion 3.092(1.926-4.965) <0.0001
T3/4 vs. T0-2 3.920(1.953-7.869) 0.00012
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2.4 Overall survival
HR (95% CI) p
Demographic Age 1.036 (1.015-1.057) 0.001
Gender (male) 1.131 (0.737-1.735) 0.573
SIMD quintile vs. most 
deprived
2 1.361 (0.581-3.187) 0.478
3 1.876 (0.805-4.374) 0.145
4 0.956 (0.408-2.238) 0.917
5 0.760 (0.324-1.780) 0.527
Treatment SCRT vs. Surgery alone 0.931 (0.587-1.479) 0.763
Adjuvant chemotherapy 0.693 (0.399-1.202) 0.192
APER vs. other operation 1.563 (0.884-2.765) 0.125
Upper third vs. mid/lower 0.927 (0.594-1.448) 0.740
Incomplete mesor ctal fascia 1.255 (0.757-2.079) 0.378
Pathology Positive CRM 3.361 (1.899-5.948) <0.0001
Poor differentiation 3.615 (2.178-5.999) <0.0001
Nodal status vs. N0
N1 1.184 (0.727-1.930) 0.497
N2 2.488 (1.515-4.085) <0.0001
N+ vs N- 1.592 (1.067-2.376) 0.023
Lymph node ratio 10.593 (4.716-23.794) <0.0001
Lymphovascular invasion 2.271 (1.515-3.404) <0.0001
T3/4 vs. T0-2 2.169 (1.337-3.520) 0.002
SIMD, Scottish Index of Multiple Deprivation
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